Controversial Juul E-cigarettes Removed from Market by FDA

Jun.24.2022

All Juul e-cigarette products are being taken off the market by the FDA due to potentially harmful chemicals.

The US Food and Drug Administration has removed all electronic cigarette products manufactured by controversial company Juul, but not for the reasons one might expect.

The US Food and Drug Administration (FDA) has announced its plans to remove Juul products from the market. This decision is based on toxicology data and the potential risk of harmful chemicals that have been found to seep out from the company's proprietary pods, rather than their appeal to young people.

This move by the FDA is the most significant action taken to date against a major tobacco company and could spell disaster for the Juul brand.

#Juul #FDA #E-cigarette #E-cigarettes and Tobacco #E-cigarette Market

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

BAT Expects Around 2% Revenue and Operating Profit Growth in FY25

British American Tobacco (BAT) reaffirmed its 2026 guidance while announcing a £1.3 billion (approximately USD 1.65 billion) share buyback for FY26. The company expects around 2% growth in revenue and adjusted profit from operations for FY25. Accelerating New Category growth, driven by Velo Plus and improving U.S. Vuse performance, is expected to deliver double-digit H2 revenue growth.

Dec.09 by 2FIRSTS.ai

Imperial Brands FY25 Results: NGP Net Revenue Up 13.7%, Americas Surges Nearly 70%

Imperial Brands reported FY25 NGP net revenue of £368 million, up 13.7% at constant currency. Growth in the Americas accelerated sharply, with NGP revenue up 69.8%, driven by the expansion of the modern oral brand Zone. Europe delivered 8.8% growth, supported by blu’s double-digit vapour share across key markets. Adjusted NGP operating losses narrowed to £76 million, putting the category closer to breakeven.

Nov.18 by 2FIRSTS.ai

Poland Plans Total Prohibition of Single-Use Vapes to Protect Youth

Poland’s Ministry of Health has proposed legislation to ban all disposable e-cigarettes — both with and without nicotine — under a new amendment to tobacco product laws. The government aims to protect youth from nicotine addiction while reducing public health and environmental harm. Medical professionals largely support the move but call for balanced harm-reduction strategies.

Nov.25 by 2FIRSTS.ai

5th Circuit Reviews FDA’s Compliance on Small-Business Impact of Vape Rule

A Fifth Circuit panel expressed doubts about whether the U.S. Food and Drug Administration complied with the Regulatory Flexibility Act when issuing its 2021 final rule on premarket tobacco product applications. Vape companies argued the FDA relied on outdated and inaccurate economic data, while the government said the challenged requirements stem from the Tobacco Control Act.

Dec.03 by 2FIRSTS.ai